Canaccord Genuity set a $12.00 price objective on Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) in a report issued on Wednesday. The firm currently has a buy rating on the biotechnology company’s stock.

Other equities research analysts have also issued reports about the stock. HC Wainwright set a $18.00 price objective on shares of Aldeyra Therapeutics and gave the stock a buy rating in a report on Saturday, April 1st. Cowen and Company reaffirmed a buy rating and issued a $20.00 target price on shares of Aldeyra Therapeutics in a research report on Friday, March 31st. Zacks Investment Research raised shares of Aldeyra Therapeutics from a hold rating to a buy rating and set a $5.50 target price for the company in a research report on Friday, March 24th. Finally, Stifel Nicolaus reaffirmed a buy rating and issued a $16.00 target price on shares of Aldeyra Therapeutics in a research report on Wednesday, May 31st. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $14.30.

Aldeyra Therapeutics (ALDX) opened at 4.45 on Wednesday. The stock’s 50 day moving average is $4.56 and its 200 day moving average is $4.91. Aldeyra Therapeutics has a 12-month low of $3.80 and a 12-month high of $8.19. The stock’s market capitalization is $27.79 million.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings data on Monday, May 15th. The biotechnology company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by $0.04. Analysts forecast that Aldeyra Therapeutics will post ($1.52) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/06/20/canaccord-genuity-analysts-give-aldeyra-therapeutics-inc-aldx-a-12-00-price-target.html.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC purchased a new position in shares of Aldeyra Therapeutics during the first quarter worth approximately $132,000. Hikari Power Ltd purchased a new position in shares of Aldeyra Therapeutics during the first quarter worth approximately $188,000. Geode Capital Management LLC increased its position in shares of Aldeyra Therapeutics by 3.6% in the first quarter. Geode Capital Management LLC now owns 54,888 shares of the biotechnology company’s stock worth $274,000 after buying an additional 1,912 shares during the period. Sabby Management LLC purchased a new position in shares of Aldeyra Therapeutics during the first quarter worth approximately $898,000. Finally, Vanguard Group Inc. increased its position in shares of Aldeyra Therapeutics by 102.9% in the first quarter. Vanguard Group Inc. now owns 295,226 shares of the biotechnology company’s stock worth $1,476,000 after buying an additional 149,754 shares during the period. 58.25% of the stock is owned by institutional investors.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.

Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.